We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
-5.15%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$325M
AUM Growth
+$325M
Cap. Flow
+$154M
Cap. Flow %
47.4%
Top 10 Hldgs %
48.17%
Holding
91
New
22
Increased
30
Reduced
16
Closed
21

Top Buys

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$9.77M
2
VCYT icon
Veracyte
VCYT
+$5.92M
3
ORIC icon
Oric Pharmaceuticals
ORIC
+$4.32M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$4.3M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$3.98M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$9.72M
2
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$4.45M
3
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
+$1.55M
4
IMGN
Immunogen Inc
IMGN
+$993K
5
IMTX icon
Immatics
IMTX
+$714K

Sector Composition

Rank Sector Weight
1 Healthcare 64.89%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISEE
26
PUT
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$4.14M 1.28%
430,900
+336,300
+355% +$4.22M
MRSN
27
DELISTED
Mersana Therapeutics
MRSN
$3.93M 1.21%
+34,000
New +$3.2M
APEN
28
DELISTED
Apollo Endosurgery, Inc.
APEN
$3.92M 1.21%
1,074,879
+70,480
+7% +$333K
BHVN
29
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$3.84M 1.18%
26,374
-76,123
-74% -$9.72M
UTHR icon
30
United Therapeutics
UTHR
$26.3B
$3.82M 1.18%
16,227
+1,391
+9% +$283K
IMTX icon
31
Immatics
IMTX
$1.18B
$3.09M 0.95%
355,103
-90,231
-20% -$714K
VRTX icon
32
Vertex Pharmaceuticals
VRTX
$122B
$2.94M 0.9%
10,414
+2,776
+36% +$743K
CGEM icon
33
Cullinan Oncology
CGEM
$1.07B
$2.73M 0.84%
+213,090
New +$2.42M
CRNX icon
34
Crinetics Pharmaceuticals
CRNX
$8.87B
$2.6M 0.8%
139,539
+25,535
+22% +$510K
RGNX icon
35
Regenxbio
RGNX
$622M
$2.57M 0.79%
+104,129
New +$2.6M
AKRO
36
DELISTED
Akero Therapeutics
AKRO
$2.46M 0.76%
+260,325
New +$2.71M
MRTX
37
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.44M 0.75%
36,403
-9,719
-21% -$618K
OTIC
38
DELISTED
Otonomy, Inc.
OTIC
$2.17M 0.67%
1,041,273
-166,112
-14% -$346K
CLYM
39
Climb Bio
CLYM
$732M
$2.15M 0.66%
713,009
+624,730
+708% +$2.96M
SNDX icon
40
Syndax Pharmaceuticals
SNDX
$1.82B
$2.08M 0.64%
107,852
+6,405
+6% +$107K
PHR icon
41
Phreesia
PHR
$657M
$1.95M 0.6%
+78,111
New +$1.72M
VRAY
42
DELISTED
ViewRay, Inc.
VRAY
$1.94M 0.6%
732,740
+296,644
+68% +$893K
DAWN
43
DELISTED
Day One Biopharmaceuticals
DAWN
$1.89M 0.58%
+105,476
New +$1.09M
IMGN
44
DELISTED
Immunogen Inc
IMGN
$1.87M 0.58%
416,479
-228,521
-35% -$993K
CVRX icon
45
CVRx
CVRX
$129M
$1.76M 0.54%
+292,145
New +$1.68M
EYPT icon
46
EyePoint Inc
EYPT
$1.04B
$1.55M 0.48%
197,640
+11,974
+6% +$120K
CDXS icon
47
Codexis
CDXS
$141M
$1.44M 0.44%
137,960
+56,960
+70% +$714K
HGEN
48
PUT
DELISTED
HUMANIGEN, INC.
HGEN
$1.38M 0.43%
+781,100
New +$1.75M
NKTX icon
49
Nkarta
NKTX
$162M
$1.36M 0.42%
+110,763
New +$1.45M
AMYT
50
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$1.23M 0.38%
176,309
+23,042
+15% +$180K
1
2
3 4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
EWA
Evolution Wealth Advisors Aventura, Florida $981M AUM 21.2% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
PE
PSG Equity Boston, Massachusetts $977M AUM 13.39% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return

Silverarc Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, Silverarc Capital Management held 91 positions worth $325M, up 134,306% from $242K the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Silverarc Capital Management deployed $154M of net new capital in Q2 2022, opening 22 new positions and adding to 30 existing holdings. Its largest new stake was Oric Pharmaceuticals: 1,082,304 shares worth $4.85M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, down from 85% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Biohaven Pharmaceutical Holding Company Ltd., an estimated $9.72M trimmed.

  • Silverarc Capital Management's largest Q2 2022 buy was Oric Pharmaceuticals: 1,082,304 shares worth $4.85M.
  • Silverarc Capital Management added most to Morphic Holding, Inc. Common Stock in Q2 2022, an estimated $9.77M increase.
  • Silverarc Capital Management's biggest Q2 2022 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $9.72M.
  • Silverarc Capital Management fully exited LeonaBio Inc in Q2 2022, selling an estimated $27K.
  • Silverarc Capital Management's ten largest holdings make up 48% of its $325M portfolio in Q2 2022.
  • Silverarc Capital Management opened 22 new positions and closed 21 in Q2 2022.
  • Silverarc Capital Management's portfolio value rose 134,306% quarter-over-quarter to $325M.

Based on Silverarc Capital Management's 13F filing for Q2 2022, filed 25 Jul 2022.